Janssen Pharmaceutical K.K. and Taiwan University Team Up to Fight Hepatitis B

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

June 4, 2013 -- Janssen Pharma and the National Taiwan University Hospital will co-develop new drugs for hepatitis B. Janssen, the drug development subsidiary of Johnson & Johnson, will supply drug candidates to Pei-jer Chen, MD, a noted hepatitis B researcher at NTU College of Medicine. Dr. Chen will test how patients and the disease react to the compounds. The company expects to spend $7 million on the project in its first three years. More details....

Stock Symbol: (NYSE: JNJ)



Help employers find you! Check out all the jobs and post your resume.

Back to news